Here is the rundown on market activity for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). CMO and EVP – Development David Shapiro sold 3,545 shares at an average price of $165.40 on September 26th. That brings Shapiro’s holdings to $7,417,528 as recorded in a recent Form 4 SEC filing. Lisa Bright, President of International sold $39,114 worth of shares at an average price of $159.00 on Thu the 25th. The President of International now owns $2,935,140 of the stock per an SEC filing yesterday.
CAO Barbara Gayle Duncan let go of 146 shares at an average price of $145.11 on Tue the 5th. That brings the CAO’s holdings to $4,470,549 as reported to the SEC.
Here are a few other firms who have also updated their positions. As of quarter end Macquarie Group Ltd had bought 12,788 shares growing its holdings by 129.1%. The value of the company’s investment in Intercept Pharmaceuticals, Inc. increased from $1,272,000 to $3,237,000 a change of 154.5% quarter to quarter. Twin Tree Management, Lp downsized its position by selling 6,900 shares a decrease of 64.5%. Twin Tree Management, Lp controls 3,800 shares with a value of $568,000. The total value of its holdings decreased 78.0%.
As of the end of the quarter Royal Bank Of Canada had acquired a total of 48 shares growing its position 342.9%. The value of the investment in ICPT went from $2,000 to $9,000 increasing 350.0% for the reporting period. As of the end of the quarter Ifp Advisors, Inc had sold 199 shares trimming its stake by 25.9%. The value in dollars decreased from $99,000 to $81,000 a change of $18,000 quarter over quarter.
Equity analyst Cantor Fitzgerald added the stock to its research portfolio with an initial rating of “Sell” and establishing a price target of $58.00. May 31 investment analysts at Goldman Sachs kept the stock rating at “Outperform” but moved up the price target to $215.00 from $114.00.
On May 31 Morgan Stanley held the company rating at “Outperform” but raised the price expectation from $80.00 to $215.00. On May 31 Cowen & Company kept the company rating at “Outperform” but lowered the price target from $420.00 to $215.00.
Morgan Stanley lowered the price target and downgraded the stock on April 8 changing the price target from $100.00 to $80.00 and setting the rating at “Underperform” which had previously been “Equal-weight”. On April 8 the company was downgraded to “Underperform” from “Equal-weight” and a price target of $80.00 was set in a report from Morgan Stanley.
The company is so far trading down by -2.59% since yesterday’s close of $172.13. Shares of the company are trading at $167.68 slightly over $158.72, the 50 day moving average and just above the 200 day moving average of $148.97. The 50 day moving average was up $8.96 or +5.64% and the 200 day average went up by +12.56%.
As of the last earnings report the EPS was $-14.05 and is projected to be $-16.31 for the current year with 24,726,000 shares currently outstanding. Analysts expect next quarter’s EPS will be $-4.09 with next year’s EPS projected to be $-14.77.
Traders are more bullish on Intercept Pharmaceuticals, Inc. of late if you watch the decrease in short interest. The stock recorded a fall in short interest between August 31, 2016 and September 15, 2016 of -0.05%. Short interest fell 204,769 over that timeframe. Days to cover decreased from 13.4 to 12.4 and the percentage of shorted shares is 0.17% as of September 15.